Evidence map›Paper›PMID 42071157›Full record

ReviewAdvances in experimental medicine and biology2026

Applications of Metabolomics in the Development of Biomedicine and Biotechnology.

Eric H Rosenn, Allison Walker-Elders, Murugesh Padmanarayana, Aditya Upadhayay, Aditya Kumar Sharma, Neha Dubey, Yogita Soni, Vijay Soni

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eric H RosennDepartment of Biomedical Engineering, New York University, Tandon School of Engineering, New York, NY, USA.
Allison Walker-EldersCollege of Osteopathic Medicine, Touro University, New York, NY, USA.
Murugesh PadmanarayanaDepartment of Biochemistry, Stanford University, Beckman Center for Molecular and Genetic Medicine, Stanford, Palo Alto, CA, USA.
Aditya UpadhayayHospital for Special Surgery, New York, NY, USA.
Aditya Kumar SharmaDepartment of Pathology, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Neha DubeyDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO, USA.
Yogita SoniDepartment of Chemical and Biological Engineering, Tufts University, Medford, MA, USA.
Vijay SoniDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA. vis2032@med.cornell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolomics has emerged as a powerful discipline for capturing dynamic biochemical states and linking molecular processes to human health, disease, and biotechnology. This chapter explores the evolution of metabolomics from early profiling efforts to its current integration with advanced analytical platforms, computational biology, and precision medicine. We highlight how targeted and untargeted metabolomic strategies have advanced biomarker discovery, clarified disease mechanisms, and informed the development of personalized therapies in cancer, cardiovascular disease, diabetes, and other conditions. The role of pharmacometabolomics in refining drug response predictions and guiding therapeutic decisions is also examined. Beyond biomedicine, metabolomics drives innovation in biotechnology, synthetic biology, and bio-based production, while emerging tools such as single-cell metabolomics and machine learning continue to expand its scope. By directly tracing metabolic fluxes and engineering new pathways, metabolomics is becoming a practical engine for designing microbes, optimizing bioprocesses, and accelerating drug discovery.

Indexed as

Biomedical ResearchBiotechnologyMetabolomicsAnimalsBiomarkersDrug DiscoveryHumansPrecision MedicineBiomarkersBiomarkersBiosynthetic pathwaysDrug-target interactionsHost-pathogen relationshipsMetabolomeOncometabolitesPersonalized medicinePharmacometabolomicsSynthetic biology

Identifiers

PMID42071157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.